APGE: Apogee Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,860.82
Enterprise Value ($M) 1,742.04
Book Value ($M) 734.40
Book Value / Share 16.92
Price / Book 2.53
NCAV ($M) 492.60
NCAV / Share 11.35
Price / NCAV 3.78

Profitability (mra)
Return on Invested Capital (ROIC) -0.20
Return on Assets (ROA) -0.34
Return on Equity (ROE) -0.36

Liquidity (mrq)
Quick Ratio 16.39
Current Ratio 16.39

Balance Sheet (mrq) ($M)
Current Assets 534.48
Assets 776.29
Liabilities 41.88
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
9 days ago 13G/A Ra Capital Management, L.p. 3.40 -0.81
9 days ago 13G/A Deep Track Capital, LP 2.22 -56.96
9 days ago 13G Driehaus Capital Management Llc 5.63
11-12 13G/A Fmr Llc 16.67 49.49
11-08 13G BlackRock, Inc. 6.60 0.00
11-04 13G/A Access Industries Management, Llc 4.87 12.88
10-04 13G Wellington Management Group Llp 10.70
04-01 13D/A Fairmount Funds Management LLC 9.99 -11.85

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-03-05 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark one)

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-22 166,405 457,776 36.35
2024-11-21 123,184 420,334 29.31
2024-11-20 97,166 290,319 33.47
2024-11-19 85,920 287,717 29.86
2024-11-18 130,514 521,870 25.01

(click for more detail)

Similar Companies
AFMD – Affimed N.V. ALT – Altimmune, Inc.
ANIP – ANI Pharmaceuticals, Inc. APLT – Applied Therapeutics, Inc.
AQST – Aquestive Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io